Targeted agents that display activity in treating other lung cancer sub-types (e.g., EGFR- and ALK-inhibitors in NSCLC) are relatively ineffective for SCLC because these pathways are generally not dysregulated in SCLC [49]. Here, EGFR is linked to lung cancer.